AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The funding was led by Green Pine Capital Partners, with contributions from ZDVC and existing investor HM Capital, among others. This investment will support the company’s ongoing development and expansion in the ophthalmology sector.
Company Overview and Achievements
Founded in 2014, AmVision Bio is known for developing innovative ophthalmology solutions. The company boasts the first approved cryopreserved biological amnion product in China, which has been a significant milestone in the field. Additionally, AmVision Bio has licensed Epicon A, a scleroscope product from an Australian firm, which is expected to obtain market approval in the first half of this year.
Product Development and Future Plans
AmVision Biotech is actively developing products in various areas of ophthalmology, including ocular surface, optometry, glaucoma, and fundus macular hole fields. The Series A+ financing will provide the necessary resources to accelerate the development of these products and enhance the company’s market presence.
Significance of the Funding
This funding round underscores AmVision Biotech’s commitment to advancing cutting-edge ophthalmology devices and improving eye care solutions. By leveraging the expertise and support of its investors, the company aims to bring innovative products to market, benefiting patients and healthcare providers alike.-Fineline Info & Tech
